戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 plement regulatory protein CD55 (also termed decay-accelerating factor).
2 membrane complement regulatory protein CD55 (decay-accelerating factor).
3 the phosphatidylinositol linkage domain from decay accelerating factor.
4 lated adhesins recognize the common receptor decay accelerating factor.
5 , whereas CB1, CB3, and CB5 may also bind to decay accelerating factor.
6 acting with a complement-regulatory protein, decay-accelerating factor.
7 ent-regulatory proteins human CD59 and human decay-accelerating factor.
8 phosphatidylinositol (GPI) anchor from human decay-accelerating factor.
9 merization with the GPI signal sequence from decay-accelerating factor.
10  membrane cofactor protein were swapped into decay-accelerating factor.
11 n of complement inhibitory proteins CD59 and decay-accelerating factor.
12 to display a reduced capacity for clustering decay-accelerating factor.
13                                Deficiency of decay-accelerating factor 1 (termed Daf1 in mice) has be
14 ycosyl-phosphatidylinositol-anchored protein decay accelerating factor, a lipid raft protein.
15 ered truncations and molecular chimeras with decay-accelerating factor, a related protein in the fami
16 hearts from transgenic pigs expressing human decay-accelerating factor and CD59 underwent acute vascu
17 51 of CD14 fused to the C-terminal region of decay-accelerating factor and expressed it in Chinese ha
18 e C3 convertase, even after decay induced by decay-accelerating factor and factor H, as assayed by su
19 al analog of the human complement inhibitors decay-accelerating factor and membrane cofactor protein.
20 ell as to the complement-regulatory proteins decay-accelerating factor and membrane cofactor protein.
21  livers used were transgenic for human CD55 (decay-accelerating factor) and human CD59.
22 ibitors (C' receptor-1 related isoform Y and decay accelerating factor), and an increase in local TUN
23 nitiates immune evasion through induction of decay accelerating factor, and transactivates peroxisome
24 ines was correlated with low levels of CD59, decay-accelerating factor, and membrane cofactor protein
25  reported that E. coli Dr adhesin recognizes decay-accelerating factor as the host tissue receptor an
26 y, the four short consensus repeats of human decay accelerating factor (CD55) linked to IgG4 Fc and t
27 hypothesis that increasing the expression of decay accelerating factor (CD55) on RPE cells may result
28                                              Decay-accelerating factor (CD55) accelerates the decay o
29           The LU30 antigen was identified as decay-accelerating factor (CD55) by expression cloning f
30 n of echovirus 11 with its cellular receptor decay-accelerating factor (CD55).
31 oteins, membrane cofactor protein (CD46) and decay-accelerating factor (CD55).
32  activation pathway, as well as mice lacking decay-accelerating factor (CD55/DAF), a complement regul
33 om known decay accelerating factors, such as decay accelerating factor, complement receptor 1, and fa
34 boons received xenotransplants of both human decay-accelerating factor composite thymokidneys and ome
35                 The extracellular portion of decay-accelerating factor comprises four short consensus
36 he membrane co-factor protein (MCP or CD46), decay accelerating factor (DAF or CD55) and CD59, indica
37 reas in .48 transfectants the GPI anchors in decay accelerating factor (DAF) and placental alkaline p
38                                              Decay accelerating factor (DAF) is not a cell receptor f
39  forms of the membrane complement inhibitors decay accelerating factor (DAF) or CD59.
40 plement system and adaptive immunity is that decay accelerating factor (DAF), a cell surface C3/C5 co
41 e short consensus repeat-3 (SCR-3) domain of decay accelerating factor (DAF), a complement regulatory
42 lpha chain, membrane cofactor protein (MCP), decay accelerating factor (DAF), and complement receptor
43 icient in the complement regulatory protein, decay accelerating factor (DAF), and/or the complement c
44 Complement-activation controllers, including decay accelerating factor (DAF), are gaining emphasis as
45 hough many coxsackie B viruses interact with decay accelerating factor (DAF), attachment to DAF by it
46 in 2, cbp/p300-interacting transactivator 2, decay accelerating factor (DAF), vascular cell adhesion
47  soluble chimeric protein derived from human decay accelerating factor (DAF, CD55) and membrane cofac
48 ciency of the complement inhibitory proteins decay accelerating factor (DAF, CD55) and membrane inhib
49 ing sites for factors B, H and I, properdin, decay accelerating factor (DAF, CD55), membrane cofactor
50 eptor type 1 (CR1, CD35: Knops antigens) and decay accelerating factor (DAF, CD55: Cromer antigens).
51 e cognate receptors of live virions, namely, decay accelerating factor (DAF/CD55) expressed on Tanoue
52            The complement regulatory protein decay accelerating factor (DAF; CD55), inhibits the alte
53 rotein possessing the functions of the human decay-accelerating factor (DAF [CD55]) and membrane cofa
54                                              Decay-accelerating factor (DAF or CD55) and CD59 are reg
55                                              Decay-accelerating factor (DAF or CD55) and membrane cof
56 tween echovirus 11 strain 207 (EV11-207) and decay-accelerating factor (DAF or CD55) at the apical su
57                                              Decay-accelerating factor (DAF or CD55) is expressed on
58            The complement regulatory protein decay-accelerating factor (DAF or CD55) protects host ti
59            The complement regulatory protein decay-accelerating factor (DAF or CD55) was induced foll
60 tudy we investigated whether the presence of decay-accelerating factor (DAF or CD55), an intrinsic co
61  passaged in the CAR-poor RD cell line binds decay-accelerating factor (DAF) (CD55) and CAR.
62 ediated cleavage of C3b into iC3b as well as decay-accelerating factor (DAF) activity against the C3
63 enic, and adhesive subunit, which recognizes decay-accelerating factor (DAF) and carcinoembryonic ant
64 ns adheres to epithelial cells by binding to decay-accelerating factor (DAF) and carcinoembryonic ant
65                                              Decay-accelerating factor (DAF) and CD59 are 2 glycosylp
66 We previously developed a renal IRI model in decay-accelerating factor (DAF) and CD59 double-knockout
67                                              Decay-accelerating factor (DAF) and complement receptor
68  (EV) and Coxsackie B virus (CBV) bind human decay-accelerating factor (DAF) and use it as a receptor
69 receptor 1-related gene/protein y (Crry) and decay-accelerating factor (DAF) are two murine membrane
70 f invading epithelial cells recognizes human decay-accelerating factor (DAF) as its cellular receptor
71                         Many echoviruses use decay-accelerating factor (DAF) as their cellular recept
72  recognize the complement regulatory protein decay-accelerating factor (DAF) as their receptor.
73 Many coxsackievirus B isolates bind to human decay-accelerating factor (DAF) as well as to the coxsac
74 oxsackievirus B (CVB) isolates bind to human decay-accelerating factor (DAF) as well as to the coxsac
75 B entry into placental trophoblasts requires decay-accelerating factor (DAF) binding and involves rel
76                                              Decay-accelerating factor (Daf) dissociates C3/C5 conver
77 ecreased membrane cofactor protein (MCP) and decay-accelerating factor (DAF) expression on endothelia
78                                              Decay-accelerating factor (DAF) has been identified as a
79                                              Decay-accelerating factor (DAF) has been reported to be
80 coxsackievirus-adenovirus receptor (CAR) and decay-accelerating factor (DAF) have been identified as
81 lecule that binds into the viral canyon, and decay-accelerating factor (DAF) have been identified as
82                                              Decay-accelerating factor (DAF) is a cell surface regula
83                                              Decay-accelerating factor (DAF) is a cell-associated C r
84                                              Decay-accelerating factor (DAF) is a cellular receptor f
85                                              Decay-accelerating factor (DAF) is a complement regulato
86                                              Decay-accelerating factor (DAF) is a glycosylphosphatidy
87                                              Decay-accelerating factor (DAF) is a glycosylphosphatidy
88                                              Decay-accelerating factor (DAF) is a widely expressed, m
89 (GPI)-anchored complement regulatory protein decay-accelerating factor (DAF) is used by a number of e
90  have evaluated the effect of the absence of decay-accelerating factor (DAF) on cardiac allograft rej
91       We show here that deficiency of either decay-accelerating factor (DAF) or complement receptor 1
92 and diarrhoea-associated Escherichia coli to decay-accelerating factor (DAF) present on erythrocytes
93 ent vasculoprotective pathway, which induced decay-accelerating factor (DAF) promoter activity via bi
94              Escherichia coli Dr adhesin and decay-accelerating factor (DAF) receptor-mediated intera
95                                              Decay-accelerating factor (DAF), a complement regulatory
96 ave isolated a murine homologue of the human decay-accelerating factor (DAF), a glycosylphosphatidyli
97            Here we studied mice deficient in decay-accelerating factor (DAF), a key membrane compleme
98                                              Decay-accelerating factor (DAF), a membrane-bound comple
99 nto the mucosal surface by goblet cells, and decay-accelerating factor (DAF), a protein produced by c
100                                              Decay-accelerating factor (DAF), a protein that protects
101  B3 (CVB3) depends on virus interaction with decay-accelerating factor (DAF), a receptor expressed on
102 s revealed that the endogenous expression of decay-accelerating factor (DAF), an inhibitor of complem
103 epletion of membrane cofactor protein (MCP), decay-accelerating factor (DAF), and CD59 on inhibitory
104 E-associated complement receptor 1 (CR1) and decay-accelerating factor (DAF), and pronounced splenic
105 d versions of the human complement inhibitor decay-accelerating factor (DAF), as a fusion protein fro
106  the cell surface C3/C5 convertase inhibitor decay-accelerating factor (DAF), but not the combined ab
107 e deficient in the key complement regulator, decay-accelerating factor (DAF), but not WT or CD59-defi
108                        Some CVB also bind to decay-accelerating factor (DAF), but that interaction al
109 he distribution of the complement inhibitors decay-accelerating factor (DAF), CD59 (protectin), and m
110  Although the complement-regulatory proteins decay-accelerating factor (DAF), CD59, and membrane cofa
111          Dr adhesins have been shown to bind decay-accelerating factor (DAF), collagen IV, and carcin
112 ) of these central enzymes by the regulators decay-accelerating factor (DAF), complement receptor 1 (
113 reated with atorvastatin or simvastatin, and decay-accelerating factor (DAF), membrane cofactor prote
114       Although some CB isolates also bind to decay-accelerating factor (DAF), the role of DAF interac
115 tor 1-related gene/protein y (Crry), but not decay-accelerating factor (DAF), were spontaneously elim
116 a cDNA coding for the last 37 amino acids of decay-accelerating factor (DAF), which contains the sign
117  to the Dr(a) blood-group antigen present on decay-accelerating factor (DAF).
118 mplement regulatory and signalling molecule, decay-accelerating factor (DAF).
119 PI modification signal sequence derived from decay-accelerating factor (DAF).
120 embrane cofactor protein (MCP), and membrane decay-accelerating factor (DAF).
121 lement activation, mediated via induction of decay-accelerating factor (DAF).
122 ficient in the membrane complement inhibitor decay-accelerating factor (DAF).
123  also interact with the GPI-anchored protein decay-accelerating factor (DAF).
124 for Dr adhesins is the cell surface protein, decay-accelerating factor (DAF).
125 -fimbriated E. coli are type IV collagen and decay-accelerating factor (DAF).
126 pression on chromosome 1 were those encoding decay-accelerating factor (DAF, also known as CD55) and
127                                              Decay-accelerating factor (DAF, also known as CD55), a g
128        Data presented show that targeting of decay-accelerating factor (DAF, an inhibitor of compleme
129 iridae family, uses the complement regulator decay-accelerating factor (DAF, CD55) as a cellular rece
130                                              Decay-accelerating factor (DAF, CD55) is a glycosylphosp
131                                              Decay-accelerating factor (DAF, CD55) is a GPI-anchored
132 (CCP) modules of the cell surface regulator, decay-accelerating factor (DAF, CD55), comprise the simp
133 analysis revealed that OE-1 recognized human decay-accelerating factor (DAF, CD55).
134 he expression level of the cellular receptor decay-accelerating factor (DAF; CD55).
135                                              Decay-accelerating factor ([DAF] CD55) is a glycosylphos
136 rast, CD4-deficient chimeric mice possessing decay accelerating factor deficient (Daf1(-/-)) bone mar
137 , under the direction of the GPI signal from decay accelerating factor, directs hGH cell surface expr
138  in which low levels of human CD59 and human decay-accelerating factor expression significantly effec
139 on of CD59 was up-regulated by 100%, whereas decay-accelerating factor expression was unchanged.
140 , src, hck, CD4, CD45, G proteins, and CD55 (decay-accelerating factor) expression in the buoyant low
141  vesicles also showed enrichment of albumin, decay-accelerating factor, Fc gammaRIII, and CR3; wherea
142 rm survival of nonhuman primates using human decay-accelerating factor (hDAF) transgenic pig organs a
143 miniature swine or pigs transgenic for human decay-accelerating factor (hDAF) were transplanted into
144 c for a human complement regulatory protein, decay-accelerating factor (hDAF), were major advances.
145 n regulators of complement activation (human decay-accelerating factor [hDAF] and hCD59).
146 3; mTOR, mammalian target of rapamycin; DAF, decay-accelerating factor; IKK, IkappaB kinase; IRF, int
147 expressing adhesins of the Dr family bind to decay-accelerating factor, invade epithelial cells, pref
148 dicates that interaction of Dr fimbriae with decay-accelerating factor is associated with redistribut
149 or density, and in situ hybridization of Dr (decaying-accelerating factor) ligands for Escherichia co
150 H2-terminal short consensus repeats of human decay accelerating factor linked to IgG2 Fc have been de
151 NADPH oxidase activity, whereas VEGF-induced decay-accelerating factor-mediated protection of endothe
152 o up-regulation of the complement regulators decay accelerating factor, membrane cofactor protein, an
153 e fimbriated and others afimbriated, bind to decay-accelerating factor molecules on human cells.
154                           The mean number of decay-accelerating factor molecules on the surface of 12
155                                Allo-HCT with decay accelerating factor-null (Daf1(-/-)) host BM and D
156 forms of either membrane cofactor protein or decay-accelerating factor or of both factors combined.
157  bind integrins alpha5beta1 and alphavbeta3, decay accelerating factor, or dermatan sulfate.
158 mplex-inbred miniature swine (n=7) and human decay-accelerating factor pigs (n=3) were transplanted i
159                 S20NS is distinct from known decay accelerating factors, such as decay accelerating f
160 s strategy allowed CFA to be introduced into decay-accelerating factor, suggesting that viral and hum
161 llular domain of an apical membrane protein, decay accelerating factor, to the basolateral membrane.
162 /-)) or homozygous (hDAF(+/+)) for the human decay accelerating factor transgene (hDAF) or their nont
163 f xenografts in baboon recipients from human decay-accelerating factor transgenic or alpha-1,3-galact
164 ymic tissue under the renal capsule of human decay-accelerating factor transgenic swine.
165 nd kidney (composite thymokidney) from human decay accelerating factor-transgenic swine were transpla
166 his model, the kidney xenografts, from human decay accelerating factor-transgenic swine, in baboons u
167 erum from transgenic pigs that express human decay accelerating factor was investigated.
168                     A major rearrangement of decay-accelerating factor was found at the adherence sit
169 ity for echovirus 11 of various fragments of decay-accelerating factor, we are able to conclude that
170  disrupted gene for the complement regulator decay accelerating factor were normal.
171 lls, cultured from pigs transgenic for human decay accelerating factor, were treated with human tumor
172 unction mutations in the gene encoding CD55 (decay-accelerating factor), which lead to loss of protei
173 D2B muscle exhibited decreased expression of decay accelerating factor, which was not dysferlin-speci
174 the use of donor organs transgenic for human decay-accelerating factor (with organ survival up to 2 m
175 nts of renal xenografts transgenic for human decay-accelerating factor, with survival between 4 and 6

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top